COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,363 Articles (22,803 medRxiv, 8,560 bioRxiv)

Most recent first Previous |  Page 1044: Articles 10431-10440  | Next

Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response
Perez-Gomez, A., Gasca-Capote, M. C., Vitalle, J., Ostos, F. J., Serna-Gallego, A., Trujillo-Rodriguez, M., Munoz-Muela, E., Giraldez-Perez, T., Praena-Segovia, J., Navarro-Amuedo, M. D., Paniagua-Garcia, M., Garcia-Gutierrez, M., Aguilar-Guisado, M., Rivas-Jeremias, I., Jimenez-Leon, M. R., Bachiller, S., Fernandez-Villar, A., Perez-Gonzalez, A., Gutierrez-Valencia, A., Rafii-El-Idrissi Benhnia, M., Weiskopf, D., Sette, A., Lopez-Cortes, L. F., Poveda, E., Ruiz-Mateos, E.
10.1101/2021.12.28.474325 — Posted: 2021-12-28
SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., Sidney, J., Filaci, G., Weiskopf, D., da Silva Antunes, R., Crotty, S., Grifoni, A., Sette, A.
10.1101/2021.12.28.474333 — Posted: 2021-12-28
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
Coleon, S., Wiedemann, A., Surenaud, M., Lacabaratz, C., Hue, S., Prague, M., Cervantes-Gonzalez, M., Wang, Z., Ellis, J., Sansoni, A., Pierini, C., Bardin, Q., Fabregue, M., Sharkaoui, S., Hoest, P., Dupaty, L., Picard, F., Centlivre, M., Ghosn, J., Thiebaut, R., Cardinaud, S., Malissen, B., Zurawski, G., Zarubica, A., Zurawski, S., Godot, V., Levy, Y.
10.1101/2021.12.28.474244 — Posted: 2021-12-28
SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron
Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M., Karim, F., Madzorera, S. V., Moyo-Gwete, T., Mennen, M., Skelem, S., Adriaanse, M., Mutithu, D., Aremu, O., Stek, C., du Bruyn, E., Van Der Mescht, M., de Beer, Z., de Villiers, T. R., Bodenstein, A., van den Berg, G., Mendes, A., Strydom, A., Venter, M., Grifoni, A., Weiskopf, D., Sette, A., Wilkinson, R. J., Bekker, L.-G., Gray, G., Ueckermann, V., Rossouw, T., Boswell, M. T., Bihman, J., Moore, P., Sigal, A., Ntusi, N. A. B., Burgers, W. A., Riou, C.
10.1101/2021.12.26.21268380 — Posted: 2021-12-28 Discussion: Onsite
Use of Baricitinib in Treatment of COVID-19: A Systematic Review
Sampath, A., Banerjee, A., Atal, S., Jhaj, R.
10.1101/2021.12.26.21268434 — Posted: 2021-12-27
Dying from COVID-19 or with COVID-19: a definitive answer through a retrospective analysis of mortality in Italy
Rovetta, A., Bhagavathula, A. S.
10.1101/2021.12.22.21268212 — Posted: 2021-12-27
The Canadian COVID-19 Experiences Survey: Study Protocol
Hall, P., Fong, G., Hitchman, S., Quah, A., Agar, T., Meng, G., Sakib, M. N., Hudson, A., Boudreau, C.
10.1101/2021.12.24.21268387 — Posted: 2021-12-27
High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron
Garret, N., Tapley, A., Andriesen, J., Seocharan, I., Fisher, L. H., Bunts, L., Espy, N., Wallis, C., Randhawa, A. K., Goga, A., Bekker, L.-G., Gray, G. E., Corey, L.
10.1101/2021.12.20.21268130 — Posted: 2021-12-27 Discussion: Onsite
Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines
May, D. H., Rubin, B. E. R., Dalai, S. C., Patel, K., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., Robins, H. S.
10.1101/2021.12.20.21267877 — Posted: 2021-12-27
Reliably Assessing Duration of Protection for COVID-19 Vaccines
Lin, D., Zeng, D., Gu, Y., Fleming, T., Krause, P.
10.1101/2021.12.22.21268201 — Posted: 2021-12-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).